The abstract is read at the publisher; the summary is JClub's.
Vutrisiran’s effect on all-cause mortality and recurrent cardiovascular events in HELIOS-B ATTR-CM patients was not statistically modified by baseline or time-updated tafamidis or heart failure therapies.
- Why it matters: It was unclear whether concomitant disease-modifying or heart failure medications change vutrisiran’s efficacy in transthyretin amyloid cardiomyopathy, a key gap for real-world treatment combinations.
- What they did: In 654 randomized HELIOS-B patients, baseline use and postrandomization initiation of tafamidis and heart failure drug classes were assessed, and time-updated Lin-Wei-Yang-Ying models tested effect modification on the primary composite endpoint.
- The result: No statistically significant interaction was found for tafamidis (P-interaction 0.95), SGLT2 inhibitors (0.59), MRAs (0.92), beta-blockers (0.75), or renin-angiotensin system inhibitors/angiotensin receptor-neprilysin inhibitors (0.82), supporting consistent efficacy across contemporary ATTR-CM pharmacotherapy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.